Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Ischemic Stroke l: Introduction01:15

Ischemic Stroke l: Introduction

Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Transient Ischemic Attack l: Introduction01:26

Transient Ischemic Attack l: Introduction

A transient ischemic attack (TIA) is a brief episode of neurological dysfunction caused by a temporary, focal reduction in cerebral blood flow. Although symptoms resemble those of an ischemic stroke, the interruption in perfusion is short-lived and does not cause permanent infarction. TIAs are clinically important because they often serve as early warning events for future stroke.Mechanisms of Transient Cerebral IschemiaTransient cerebral ischemia may arise through several mechanisms. One...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of impaired foetal maternal environment on neonates with CHD: are we ready for the mother-baby dyad?

Cardiology in the young·2026
Same author

Spinal epidural arteriovenous malformations: clinical, imaging, and angioarchitectural characteristics with endovascular treatment outcomes-a single-centre experience.

Clinical radiology·2026
Same author

Fosfomycin susceptibility in multidrug resistant uropathogens: A retrospective study in the era of antimicrobial resistance.

Journal of family medicine and primary care·2025
Same author

A case report of successful percutaneous aspiration, injection, and re-aspiration (PAIR) technique for treatment of retrovesical pelvic hydatid cyst.

Radiology case reports·2022
Same author

A Comparative Study of Osteoarthritis Knee Arthroscopy versus Intra-Articular Platelet Rich Plasma Injection: A Randomised Study.

Malaysian orthopaedic journal·2022
Same author

Cumulative comorbid conditions influence mortality risk after staged palliation for hypoplastic left heart syndrome and variants.

The Journal of thoracic and cardiovascular surgery·2022

Related Experiment Video

Updated: Jul 19, 2026

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

Antithrombotic agents in cerebral ischaemia.

P M Dalal1, N K Mishra, Madhumita Bhattacharjee

  • 1LKMM Trust Research Centre at Lilavati Hospital, Bandra Reclamation, Mumbai.

The Journal of the Association of Physicians of India
|November 9, 2006
PubMed
Summary

Aspirin is preferred for non-cardioembolic stroke, while anticoagulants benefit elderly atrial fibrillation patients. More research is needed for specific stroke types and risk factor management.

More Related Videos

A Comprehensive Approach to Analyze the Cell Components of Cerebral Blood Clots
06:12

A Comprehensive Approach to Analyze the Cell Components of Cerebral Blood Clots

Published on: July 21, 2023

Related Experiment Videos

Last Updated: Jul 19, 2026

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

A Comprehensive Approach to Analyze the Cell Components of Cerebral Blood Clots
06:12

A Comprehensive Approach to Analyze the Cell Components of Cerebral Blood Clots

Published on: July 21, 2023

Area of Science:

  • Neurology
  • Cardiology
  • Pharmacology

Background:

  • Current evidence favors aspirin over anticoagulants for non-cardioembolic stroke.
  • The efficacy of combination therapies, like aspirin with warfarin or clopidogrel, remains under investigation.
  • Anticoagulant therapy is beneficial for high-risk elderly patients with atrial fibrillation.

Purpose of the Study:

  • To review the current evidence on antithrombotic agents for stroke prevention.
  • To identify areas requiring further research in specific stroke etiologies.
  • To emphasize the importance of managing associated risk factors.

Main Methods:

  • Review of existing clinical evidence and trial data.
  • Comparative analysis of aspirin versus anticoagulant therapies.
  • Identification of knowledge gaps in antithrombotic treatment strategies.

Main Results:

  • Aspirin is the recommended treatment for non-cardioembolic stroke.
  • Combination therapy with aspirin and clopidogrel shows no added benefit.
  • Anticoagulants are crucial for elderly patients with atrial fibrillation; aspirin suits younger, low-risk individuals.

Conclusions:

  • Further randomized controlled trials are essential for cryptogenic stroke, antiphospholipid antibody syndrome, arterial dissections, and intraluminal clot syndromes.
  • Risk factor evaluation and management require increased attention in all stroke patient categories.
  • Tailoring antithrombotic therapy based on patient risk factors and stroke type is critical.